This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutExtended CoveragePK and PD ProfileGood Safety ProfileGuidelines and RecommendationsDosingRecommended DosageAdultsSpecial PopulationEfficacyIntra-abdominal InfectionRisk factorClinical efficacyUrinary Tract InfectionRisk factorClinical efficacyRespiratory Tract InfectionResistance rateImpactClinical efficacyFebrile NeutropeniaRisk factorTreatmentClinical efficacySafetyClinical & Scientific DataSupport & ResourcesSupport & ResourcesClinical UpdatesPrescribing InformationVideosWebinarsExplore Materials

Indication: Monotherapy – Sulbactam/Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory tract infections, urinary tract infections (upper and lower), intra-abdominal infections, septicaemia, meningitis, skin and soft tissue infections, bone and joint infections, endometritis and other infections in the genital tract. MAGNEX® FORTE is indicated for a specific subset of patients (patients with immunocompromised febrile neutropenic cancer, patients who have undergone a bone marrow transplant).1

Guidelines & Recommendations

The ICMR guidelines on the management of IAI with cefoperazone/sulbactam2

  • First-choice antibiotic for CA-IAI of mild-to-moderate severity2

  • Cefoperazone/Sulbactam 3 g IV 12 hourly for the treatment of IAI, specifically for biliary tract infections2

Cefoperazone/Sulbactam is effective in3



Adapted from Mazuski JE, et al. 2017.

One of the ICMR-recommended antibiotics for the treatment of UTI2

The ICMR recommends cefoperazone/sulbactam 3 g IV 12 hourly for the treatment of:



Adapted from ICMR. 2019; Bharara T, et al. 2018.

The SIS guidelines on the management of IAI: Selection of empiric antimicrobial therapy for adult patients with CA-IAI3


Adapted from Mazuski JE, et al. 2017.



CA-IAI, community-acquired intra-abdominal infection; ESBL, extended-spectrum β-lactamase; IAI, intra-abdominal infection; ICMR, Indian Council of Medical Research; IV, intravenous; SIS, Surgical Infection Society; UTI, urinary tract infection.
​​​​​​​​​​​​​​

References:

Magnex. Local product document. Pfizer; 2020. Version LPDMGX042020.

​​​​​​​​​​​​​​ICMR. Treatment Guidelines for Antimicrobial Use in Common Syndromes. 2nd ed. ICMR; 2019:1-206.

Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76.

Bharara T, Sharma A, Gur R, Duggal SD, Jena PP, Kumar A. Comparative analysis of extended-spectrum beta-lactamases producing uropathogens in outpatient and inpatient departments. Int J Health Allied Sci. 2018;7(1):45-50.


Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.


PP-MGX-IND-0555 June 2022
About


Dosing

Recommended dosage in adult ​​​​​​and special population​​​​​​​

Learn more


Efficacy

Cefoperazone/Sulbactam is recommended as an effective and well-tolerated antibiotic

Review efficacy profile


Safety

Explore the safety profile of cefoperazone/sulbactam

Review safety profile


Clinical & Scientific Data

Cefoperazone/Sulbactam is more efficient in the treatment ​​​​​​​of infection​​​​​​​

Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-MGX-IND-0555

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023